drugset / Trial / NCT05552443
A Study of Intrathecal Hydromorphone for Pediatric Idiopathic Scoliosis Repair
Non-randomizedSequentialDouble-blindTreatment
Summary
The purpose of this study is to identify a dose of intrathecal hydromorphone (opioid pain medicine) that optimizes pain control but minimizes side effects historically seen with this class of pain medications.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2024-10-27
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 2.5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 2.75 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 3 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 3.25 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 3.5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 4 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 4.5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 5.5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 6 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 6.5 ug/kg | Intrathecal |
| Subject | Hydromorphone | Other / unclassified | 7 ug/kg | Intrathecal |
Indications
No indication recorded.